Scleroderma

Scleroderma, also known as Systemic Sclerosis in its systemic form, is a rare chronic autoimmune connective tissue disease characterized by excessive collagen accumulation, fibrosis, vascular abnormalities, and progressive hardening of the skin and internal tissues. The term “Scleroderma” is derived from Greek words meaning “hard skin,” reflecting one of the most prominent manifestations of the disease. However, beyond the skin, the condition can significantly affect multiple organs and body systems, making it a complex multisystem disorder.

In Scleroderma, the immune system mistakenly attacks healthy connective tissues, triggering chronic inflammation and abnormal activation of fibroblasts, the cells responsible for collagen production. Collagen is an essential structural protein that normally supports tissue strength and elasticity, but in Scleroderma, excessive collagen deposition leads to fibrosis, tissue thickening, stiffness, and reduced flexibility. This pathological fibrosis can impair the normal functioning of the skin, blood vessels, joints, muscles, lungs, gastrointestinal tract, kidneys, and heart.

The disease may present as localized Scleroderma, primarily affecting limited skin areas, or as systemic disease involving internal organs. One of the earliest and most characteristic symptoms is Raynaud’s phenomenon, where blood vessels become excessively sensitive to cold temperatures or emotional stress, resulting in reduced blood flow, discoloration of fingers and toes, numbness, pain, and tingling sensations. Over time, chronic vascular dysfunction may contribute to tissue damage, ulcers, and impaired circulation.

Patients with Scleroderma commonly experience skin thickening, tightness, reduced joint mobility, muscle weakness, chronic fatigue, stiffness, swelling of fingers, and pain. Gastrointestinal involvement may lead to acid reflux, difficulty swallowing, bloating, indigestion, constipation, or malabsorption. Pulmonary complications such as interstitial lung disease and pulmonary hypertension are among the major causes of morbidity in systemic disease. Cardiac and renal complications may also develop in advanced cases.

Scientifically, Scleroderma is understood as a disease involving immune dysregulation, endothelial injury, chronic inflammation, oxidative stress, fibrosis, and abnormal extracellular matrix accumulation. Genetic susceptibility, autoimmune reactions, environmental triggers, hormonal influences, and vascular abnormalities are believed to contribute to disease development. Although the exact cause remains unclear, modern research increasingly focuses on the role of immune pathways, inflammatory cytokines, and fibrotic mechanisms in disease progression.

Modern medical management aims to control symptoms, reduce inflammation, slow fibrosis, improve circulation, preserve organ function, and prevent complications. Depending on disease severity and organ involvement, treatment may include immunosuppressive medications, corticosteroids, vasodilators, antifibrotic therapies, physiotherapy, respiratory rehabilitation, nutritional management, and psychosocial support. Early diagnosis and continuous monitoring are extremely important for improving long-term outcomes.